Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Milan - Delayed Quote EUR

BIOMARIN PHARMACEUTICAL (1BMRN.MI)

Compare

65.64

+0.44

+(0.67%)

At close: March 5 at 3:48:53 PM GMT+1

Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are

BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) just reported healthy earnings but the stock price didn't move much. Our...

Simply Wall St. 2 days ago

BMRN
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Investors in BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) had a good week, as its shares rose 9.7% to close at US$71.17...

Simply Wall St. 8 days ago

BMRN
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.

PR Newswire 9 days ago

BMRN
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025.

PR Newswire 10 days ago

BMRN
BioMarin price target raised to $80 from $78 at Scotiabank

Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo beat and bullish 2025 revenue outlook, the analyst tells investors. Scotiabank, however, maintains its rating due to concerns about the potential competitive threats to the Voxzogo franchise. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now

TipRanks 13 days ago

BMRN
BioMarin Pharmaceutical Full Year 2024 Earnings: Beats Expectations

BioMarin Pharmaceutical ( NASDAQ:BMRN ) Full Year 2024 Results Key Financial Results Revenue: US$2.85b (up 18% from FY...

Simply Wall St. 13 days ago

BMRN
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire 15 days ago

BMRN
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.

PR Newswire 29 days ago

BMRN
Tasso and Arup to develop blood testing services for clinical research

For launching the collaboration, Arup performed validation for several assays using capillary blood microsamples.

Medical Device Network 30 days ago

BMRN
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...

Simply Wall St. last month

BMRN
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP).

PR Newswire last month

BMRN
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California.

PR Newswire last month

BMRN
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

With its stock down 22% over the past three months, it is easy to disregard BioMarin Pharmaceutical (NASDAQ:BMRN). It...

Simply Wall St. 2 months ago

BMRN
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. These results, as well as data from the investigational research program for VOXZOGO in hypochondroplasia, were presented at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Liverpool, England, Nov. 16-18, 2024.

PR Newswire 3 months ago

BMRN
BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.

PR Newswire 3 months ago

BMRN
BioMarin price target raised to $106 from $104 at UBS

UBS raised the firm’s price target on BioMarin (BMRN) to $106 from $104 and keeps a Buy rating on the shares. BioMarin reported a solid quarter and guidance was raised incrementally on the top and bottom line, the analyst tells investors in a research note. The firm thinks the enzyme replacement therapy business alone is worth at/above where shares are trading, and thinks BMN333, which is entering the clinic in early 2025, could be a significant value driver for BioMarin in both retaining share

TipRanks 4 months ago

BMRN
BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

BioMarin Pharmaceutical ( NASDAQ:BMRN ) Third Quarter 2024 Results Key Financial Results Revenue: US$745.7m (up 28...

Simply Wall St. 4 months ago

BMRN
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter and nine months ended September 30, 2024.

PR Newswire 4 months ago

BMRN
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease that Alexion has progressed through a Phase 3 clinical trial that met its p

GlobeNewswire 4 months ago

MNPR

BMRN
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update.

PR Newswire 4 months ago

BMRN

Performance Overview

Return	1BMRN.MI	S&P 500
YTD	+3.37%	-2.43%
1-Year	-20.05%	+12.42%
3-Year	-28.17%	+32.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BIOMARIN PHARMACEUTICAL (1BMRN.MI)

Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

BioMarin price target raised to $80 from $78 at Scotiabank

BioMarin Pharmaceutical Full Year 2024 Earnings: Beats Expectations

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Tasso and Arup to develop blood testing services for clinical research

Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin price target raised to $106 from $104 at UBS

BioMarin Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Performance Overview